Larotaxel (dihydrate)
Product Specifications
UNSPSC Description
Larotaxel (dihydrate) (XRP9881 (dihydrate)), a new taxane compound prepared by partial synthesis from 10-deacetyl baccatin III, is active against tumors[1].
Target Antigen
Others
Type
Reference compound
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/larotaxel-dihydrate.html
Solubility
10 mM in DMSO
Smiles
O=C([C@]1([H])OC(C)=O)[C@@]23[C@@]([C@@H]([C@@]4(O)C(C)(C)C1=C([C@H](OC([C@H](O)[C@H](C5=CC=CC=C5)NC(OC(C)(C)C)=O)=O)C4)C)OC(C6=CC=CC=C6)=O)([H])[C@]7([C@@](OC7)([H])C[C@@H]2C3)OC(C)=O.O.O
Molecular Weight
867.93
References & Citations
[1]Liang X, et al. Degradation kinetics of larotaxel and identification of its degradation products in alkaline condition. J Pharm Anal. 2017;7(2):118-122.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-125374A/Larotaxel-dihydrate-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-125374A/
Clinical Information
Phase 3
CAS Number
192573-38-9
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
HY-66018 Inquire
N2-(1-oxohexadecyl)-L-lysyl-L-valyl-L-Lysine 2,2,2-trifluoroacetate (1:2)
Ask
View Details 